CareDx (CDNA) CEO Hanna John Walter JR Buys $327K of Stock
Hanna John Walter JR bought 39,900 shares of CareDx, valued at $327,180.
Reviewed by automated data checks against the source filing. How we make and check alerts
Hanna John Walter JR, President and CEO at CareDx, Inc. ($CDNA), bought 39,900 shares at an average price of $8.20, worth about $327,180, on June 29, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $CDNA is down 0.8% after 1 week, up 20.9% after 1 month and up 118.6% to date (from the $29.28 close on Jun 29, 2026).
CDNA
CareDx, Inc.
Key Points
- On June 29, 2026, CareDx's CEO Hanna John Walter JR bought 39,900 shares of CDNA at $8.20 each, totaling $327,180.
- CareDx's stock recently traded at $28.50, significantly lower than its 52-week high of $55.16.
- A number of analysts hold a consensus Buy rating on CareDx, with a mean price target of $54.14.
Get $CDNA trade alerts by text
We text you when insiders, Congress or big funds trade $CDNA. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated CareDx, Inc. alert may contain errors. Disclosures
CareDx CEO Makes Notable Share Purchase
On June 29, 2026, Hanna John Walter JR, President and CEO of CareDx, Inc. (NASDAQ: CDNA), bought 39,900 shares at a price of $8.20. This purchase is valued at $327,180, reflecting a personal commitment to the company.
A Look at Recent Share Movements
Hanna's recent purchase contrasts with his prior transactions, where he sold shares on June 15 and June 26, 2026. On June 15, he sold 17,683 shares at $24.03 for about $424,922, followed by a sale of 100 shares at $29.00 on June 26, amounting to $2,900. These moves show a pattern of strategic trading, as he has both sold and now bought back a significant number of shares.
Institutional Activity
So far, no other institutional investors have reported recent activity regarding CareDx shares. This lack of new institutional movements highlights that investor sentiment toward the stock remains cautious as Hanna continues to navigate his own trading strategies.
Stock Analysis
CareDx's shares are currently trading at $28.50, following a period of volatility. This price is notably lower than the stock's recent high of $55.16 within the past year, indicating potential buying opportunities for investors. The stock has fluctuated significantly, and with its current trading price, it may be appealing to those who believe in the company's growth potential.
Analysts Set New Price Targets
Analysts have expressed positive views on CareDx. On September 24, 2026, BTIG maintained a Buy rating with a target price of $74. Canaccord Genuity also initiated coverage with a Buy rating and a target of $65. This positive sentiment is reflected in the consensus, which gives CareDx a mean target price of $54.14, based on seven analyst opinions.
Understanding CareDx's Role
CareDx, Inc. focuses on improving health outcomes for transplant patients. They provide various solutions, including tests for kidney, heart, and lung transplants, which are critical in monitoring and managing transplant health. Hanna's continued investment in the company may signal his belief in its ongoing growth and the importance of its innovative health solutions.
What’s Next for CareDx
Looking ahead, investors will be watching the next earnings report scheduled for November 3, 2026. As Hanna continues to buy and sell, his trading decisions could offer insights into his confidence in CareDx's future performance. Keep in mind that this insider activity and the 13F filings reflect past positions and may not represent current holdings.
Related Filing Alerts
Source: Hanna John Walter JR's Form 4 filing on $CDNA (Jun 29, 2026). Find the original filing: CDNA Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts